tickrz reports
  
tickrz rank
D
Eli Lilly and Co (LLY)
Healthcare | Drugs
CEO: David A. Ricks
Employees: 41275
lilly.com
FACTOR RANKINGSFACTOR SCREENER 
tickrz RankD / 391Warren Buffett RankB / 237
Pure Value RankD / 421Dividend RankD / 378
Moat RankB / 227Financial Strength RankB / 215
Growth RankD / 408Momentum RankC / 307
LLY vs SECTOR & MARKET
tickrz rankP/EEV/EBITDA1yr change5yr EPS growth5yr SPS growth
LLY39139.5520.166%-7.93%-2.66%
Drugs32436.123.52.3%-37.3%13%
S&P 50021819.2911.6814.4%5.7%2.7%
DIVIDEND ANALYSIS
Dividend Yield2.52%
Payout Ratio99.13%
3 yr Dividend Growth1.34%
VALUATION RATIOS
P/E Ratio39.55x
P/B Ratio6.16x
P/S Ratio4.01x
EV/EBITDA Ratio20.16x
FINANCIAL STRENGTH
Piotroski F-Score7
Debt-to-Equity73%
Interest Coverage0x
MOAT
ROE15.01%
ROIC13.31%
Net Margin12.9%
GROWTH
5 yr EPS Growth-7.93%
5 yr SPS Growth-2.66%
5 yr BPS Growth1.7%
tickrz Report
tickrz rank D / 391
Eli Lilly and Co receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
value
pure value ranking D / 421Warren Buffett ranking B / 237
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Eli Lilly and Co's valuation score is comprised of a P/E ratio of 39.6x, a P/B ratio of 6.2x, a P/S ratio of 4x, and an EV/EBITDA ratio of 20.2x. Eli Lilly and Co ranks 421 out of the S&P 500 constituents on valuation--a relatively weak score.Eli Lilly and Co ranks 237 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Eli Lilly and Co is probably not for you.

quality
moat B / 227financial strength B / 215
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is average. Our analysis of its moat reveals neither a durable moat or enduring competitive advantages.Eli Lilly and Co has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 0x, a debt/equity ratio of 73% and a Moat Rank of 227 translate to an average Financial Strength score.


momentum C / 307
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 6.38% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 307. Based on its 12 month stock performance, Eli Lilly and Co will not appeal to momentum investors.

yield D / 378
 value + yield
Shares currently yield 2.52%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Eli Lilly and Co ranks 378 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

growth D / 408
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its -7.9% 5 year annualized EPS growth, -2.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 1.7% speak to its relatively poor ranking.

Eli Lilly and Co (LLY)
Healthcare | Drugs
CEO: David A. Ricks
Employees: 41275
lilly.com


tickrz rank
D

VALUATION RATIOS
P/E Ratio39.55x
P/B Ratio6.16x
P/S Ratio4.01x
EV/EBITDA Ratio20.16x
DIVIDEND ANALYSIS
Dividend Yield2.52%
Payout Ratio99.13%
3 yr Dividend Growth1.34%
FINANCIAL STRENGTH
Piotroski F-Score7
Debt-to-Equity73%
Interest Coverage0x
MOAT
ROE15.01%
ROIC13.31%
Net Margin12.9%
GROWTH
5 yr EPS Growth-7.93%
5 yr SPS Growth-2.66%
5 yr BPS Growth1.7%

TICKRZ RANK
Eli Lilly and Co receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Eli Lilly and Co's valuation score is comprised of a P/E ratio of 39.6x, a P/B ratio of 6.2x, a P/S ratio of 4x, and an EV/EBITDA ratio of 20.2x. Eli Lilly and Co ranks 421 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Eli Lilly and Co ranks 237 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Eli Lilly and Co is probably not for you.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is average. Our analysis of its moat reveals neither a durable moat or enduring competitive advantages.

FINANCIAL STRENGTH
Eli Lilly and Co has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 0x, a debt/equity ratio of 73% and a Moat Rank of 227 translate to an average Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 6.38% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 307. Based on its 12 month stock performance, Eli Lilly and Co will not appeal to momentum investors.

VALUE + YIELD
Shares currently yield 2.52%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Eli Lilly and Co ranks 378 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its -7.9% 5 year annualized EPS growth, -2.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 1.7% speak to its relatively poor ranking.